



Contents lists available at ScienceDirect

Chinese Chemical Letters

journal homepage: www.elsevier.com/locate/cclet

Original article

Synthesis of new penicillin derivatives as drug-like molecules for biological screening

Chun-Jing Liu^{a,*}, Dinah Dutta^a, Lester Mitscher^b^a Higuchi Biosciences Center, The University of Kansas, Lawrence KS66045, USA^b Department of Medicinal Chemistry, The University of Kansas, Lawrence KS66045, USA

ARTICLE INFO

Article history:

Received 22 May 2014

Received in revised form 8 July 2014

Accepted 22 August 2014

Available online xxx

Keywords:

Penicillin

Rearrangement

 β -Lactam antibiotics

Nucleophilic ring opening

ABSTRACT

Chemical modification of penicillin β -lactam ring was made. Six thiazolidine amides were produced through N4–C7 β -lactam ring opening of penicillin V methyl ester with various aliphatic, aromatic, and heterocyclic primary amines. Five 8-hydroxyphenilic acid derivatives with side chains of methyl, propyl, benzyl, and diethylaminoethyl groups were yielded via β -lactam ring rearrangement from 6-aminopenicillanic acid (6-APA). Parallel synthetic methods were used for the alkylation of 8-hydroxyphenilic acid and β -lactam ring opening of penicillin V methyl ester. The biological activities of the compounds were evaluated.

© 2014 Chun-Jing Liu. Published by Elsevier B.V. on behalf of Chinese Chemical Society. All rights reserved.

1. Introduction

Penicillins are β -lactam antibiotics to kill many gram-positive, gram-negative and anaerobic organisms by blocking peptidoglycan biosynthesis [1–8]. β -Lactams are 4-membered cyclic amides, depicted in 6-aminopenicillanic acid (6-APA) in Fig. 1 [9,10]. Various bonds in β -lactam can undergo cleavage to give acyclic systems or result into rearranged cyclic derivatives [11–15]. Cleavage of β -lactam bond (N4–C7) and conversion of β -lactam ring into other cyclic systems have been studied [16–18]. Nucleophilic opening of β -lactam bond using a primary amine forms thiazolidine amides [19,20].

In this paper, chemical modification of penicillin β -lactam ring was undertaken. β -Lactam ring rearrangement of 6-APA produced 8-hydroxyphenilic acid derivatives with side chains of methyl, propyl, benzyl, diethylaminoethyl, and 2-(bromomethyl)benzo[d]thiazole groups. β -Lactam ring opening of penicillin V methyl ester yielded thiazolidine amides with *p*-methoxybenzylamine, anisidine, benzyl amine, thiophene methylamine, cyclopropane methyl amine, and nonyl amine. Parallel synthetic methods were developed for esterification of 8-hydroxyphenilic acid and β -lactam ring opening of penicillin V methyl ester.

2. Experimental

Column chromatography was carried out by employing silica gel (230–400 mesh). Thin-layer chromatography (TLC) was performed on a silica gel w/uv254 uniplatTM. Anhydrous organic solvents were purchased. Parallel synthesis was conducted on Mettler Toledo MiniBlock and MiniBlock XT. Melting points were determined using a Barnstead International MET-TEMP[®] capillary melting point apparatus model 1001D-120VAC. IR spectra were measured with a Perkin ElmerTM Spectrum One FT-IR spectrometer. ¹H NMR and ¹³C NMR spectra were recorded on a 400 MHz spectrometer (400 and 100 MHz, respectively), or a 500 MHz spectrometer (500 and 125.5 MHz, respectively). Abbreviations were as follows: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet. High-resolution mass spectrometry (HRMS) spectra were obtained on a double-focusing mass spectrometer.

2.1. Procedure for synthesis of intermediate penicillin V

Potassium (2S,5R,6R)-3,3-dimethyl-7-oxo-6-(2-phenoxyacetamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate (penicillin V). To a cooled and stirred solution of 2.76 g (12.5 mmol) of 6-APA in 60 mL of water containing 5.25 g (62.5 mmol) of sodium bicarbonate, a solution of 2.76 g (16.2 mmol) phenoxyacetyl chloride in 5 mL of acetone was added in one minute. The resulting mixture was stirred vigorously during 20 min while the temperature was kept at 10–15 °C. The clear solution was

* Corresponding author.

E-mail address: cjliu2@gmail.com (C.-J. Liu).




Fig. 1. Chemical structure of 6-aminopenicillanic acid (6-APA).

extracted twice with 15 mL portions of methyl isobutyl ketone (MIBK). The clear aqueous solution was cooled to 5–10 °C and acidified to pH 2 with a cold 5.0 mol/L sulfuric acid solution. The acidified aqueous solution was extracted with 50 mL MIBK twice. The MIBK extract was separated, washed with cold water, and dried for 10 min over anhydrous sodium sulfate. After filtration, 10 mL of a 25% solution of potassium 2-ethylhexanoate in butanol was added. The white crystalline material was collected by filtration, washed on the filter with dry acetone and dried *in vacuum*, yield 3.5 g (80%) penicillin V as a white solid. Mp: 210–211 °C (dec.). ¹H NMR (400 MHz, DMSO-*d*₆): δ 8.42 (d, 1H, *J* = 8.0 Hz), 7.27 (m, 2H), 6.92 (m, 3H), 5.42 (dd, 1H, *J* = 8.0 Hz, 4.0 Hz), 5.40 (d, 1H, *J* = 4.0 Hz), 4.62 (d, 2H, *J* = 2.2 Hz), 3.88 (s, 1H), 1.52 (s, 3H), 1.46 (s, 3H); ¹³C NMR (100 MHz, DMSO-*d*₆): δ 172.8, 169.0, 168.1, 158.1, 130.0, 121.7, 115.0, 74.6, 67.3, 66.7, 65.0, 57.8, 32.7, 27.8; HRMS (FAB) calcd. for C₁₆H₁₈KN₂O₅S [M+H]⁺: *m/z* 389.0584; found: 389.0995.

2.2. Procedure for synthesis of intermediate penicillin V methyl ester (1)

(2*S*,5*R*,6*R*)-Methyl 3,3-dimethyl-7-oxo-6-(2-phenoxyacetamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate (**1**): penicillin V (388 mg, 1.0 mmol) was suspended in 10 mL of dimethylformamide (DMF). Methyl iodide (1.4 g, 12.0 mmol) was added and stirred for 1 h at room temperature. After most of the solvent was removed under reduced pressure, the mixture was loaded on silica gel column for chromatography with EtOAc/hexane (1:9) as an eluent to yield product **1** (65%) as a colorless oil. ¹H NMR (400 MHz, CDCl₃): δ 7.32 (m, 2H), 7.04 (m, 1H), 6.93 (m, 2H), 5.75 (d, 1H, *J* = 4.0 Hz), 5.60 (d, 1H, *J* = 4.0 Hz), 4.57 (s, 2H), 4.49 (s, 1H), 3.80 (s, 3H), 1.61 (s, 3H), 1.51 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 173.1, 168.1, 167.8, 156.9, 129.8, 122.4, 114.8, 70.5, 67.7, 67.1, 64.8, 58.0, 52.5, 31.8, 26.9; HRMS (FAB) calcd. for C₁₇H₂₁N₂O₅S [M+H]⁺: *m/z* 365.1170; found: 365.1194.

2.3. Procedure for synthesis of thiazolidine derivatives 2a–2f

(2*R*,4*S*)-Methyl 2-((*R*)-2-(4-methoxybenzylamino)-2-oxo-1-(2-phenoxyacetamido)ethyl)-5,5-dimethylthiazolidine-4-carboxylate (**2a**): penicillin V methyl ester (**1**, 182.0 mg, 0.5 mmol) was taken in a round-bottomed flask and 15 mL of dry methylene chloride was added. Benzyl amine (108.0 mg, 1.0 mmol) was added at room temperature and the mixture was stirred overnight. Water was added into the mixture and the mixture was extracted with methylene chloride (2 × 20 mL). After washing with brine, the organic layer was dried over NaSO₄, concentrated and purified by column chromatography with EtOAc/hexane (1:1) as the eluent to yield product **2a** (55%) as a semi-solid. ¹H NMR (400 MHz, CDCl₃): δ 7.59 (d, 1H, *J* = 7.36 Hz), 7.33–7.29 (m, 5H), 7.01 (m, 2H), 6.93 (m, 2H), 5.27 (s, 1H), 4.65 (m, 1H), 4.61 (m, 1H), 4.51 (s, 2H), 4.37 (dd, 1H, *J* = 5.9, 14.7 Hz), 3.75 (s, 3H), 3.55 (s, 2H), 1.48 (s, 3H), 1.20 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 169.9, 168.9, 168.5, 157.1, 137.7, 129.7, 128.8, 127.9, 127.6, 122.1, 114.8, 72.6, 67.2, 65.4, 58.0, 56.8, 52.3, 43.8, 26.6, 26.4; HRMS (FAB) calcd. for C₂₄H₃₀N₃O₅S [M+H]⁺: *m/z* 472.1906; found: 472.1910.

(2*R*,4*S*)-Methyl 2-((*R*)-2-(4-methoxyphenylamino)-2-oxo-1-(2-phenoxyacetamido)ethyl)-5,5-dimethylthiazolidine-4-carboxylate (**2b**): yield 62%; ¹H NMR (400 MHz, CDCl₃): δ 8.59 (s, 1H), 7.67 (d, 1H, *J* = 6.4 Hz), 7.42 (m, 2H), 7.32 (m, 2H), 6.96 (m, 1H), 6.95 (m, 2H), 6.85 (m, 2H), 5.36 (m, 1H), 4.74 (m, 1H), 4.57 (s, 2H), 3.80 (s, 3H), 3.75 (s, 3H), 3.64 (s, 1H), 1.55 (s, 3H), 1.24 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 169.8, 169.3, 166.6, 157.1, 156.7, 129.5, 129.8, 122.2, 121.8, 114.8, 114.2, 72.8, 67.3, 65.3, 58.0, 57.3, 55.5, 52.4, 26.8, 26.5; HRMS (FAB) calcd. for C₂₄H₃₀N₃O₆S [M+H]⁺: *m/z* 488.1855; found: 488.1849.

(2*R*,4*S*)-Methyl 5,5-dimethyl-2-((*R*)-2-oxo-1-(2-phenoxyacetamido)-2-(thiophen-3-ylmethylamino)ethyl)thiazolidine-4-carboxylate (**2c**): yield: 63%; ¹H NMR (400 MHz, CDCl₃): δ 7.61 (d, 1H, *J* = 7.56 Hz), 7.32 (m, 3H), 7.18 (s, 1H), 7.01 (m, 2H), 6.91 (m, 3H), 5.24 (d, 1H, *J* = 4.9 Hz), 4.72 (m, 1H), 4.62 (m, 1H), 4.52 (m, 1H), 4.50 (m, 2H), 3.73 (s, 3H), 3.56 (s, 2H), 1.47 (s, 3H), 1.18 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 169.8, 168.9, 168.4, 157.1, 140.2, 129.7, 126.9, 126.2, 125.2, 122.1, 114.8, 72.5, 67.2, 65.5, 58.0, 56.7, 52.2, 38.2, 26.6, 26.5; HRMS (FAB) calcd. for C₂₂H₂₈N₃O₅S₂ [M+H]⁺: *m/z* 478.1470; found: 478.1475.

(2*R*,4*S*)-Methyl 2-((*R*)-2-(benzylamino)-2-oxo-1-(2-phenoxyacetamido)ethyl)-5,5-dimethylthiazolidine-4-carboxylate (**2d**): yield 54%; ¹H NMR (400 MHz, CDCl₃): δ 7.48 (d, 1H, *J* = 7.4 Hz), 7.46 (d, 1H, *J* = 8.0 Hz), 7.21 (m, 2H), 7.20 (m, 2H), 7.03 (m, 1H), 6.99 (m, 2H), 6.86 (m, 2H), 5.36 (m, 1H), 5.13 (m, 1H), 4.68 (m, 1H), 4.64 (m, 1H), 4.57 (m, 2H), 4.23 (m, 1H), 3.77 (s, 3H), 3.73 (s, 3H), 1.48 (s, 3H), 1.18 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 172.8, 169.8, 168.3, 156.8, 137.8, 129.8, 128.6, 127.4, 122.0, 115.6, 74.9, 73.0, 72.4, 65.1, 58.0, 56.8, 52.3, 43.6, 26.5, 18.9; HRMS (FAB) calcd. for C₂₅H₃₂N₃O₆S [M+H]⁺: *m/z* 502.2011; found: 502.1992.

(2*R*,4*S*)-Methyl 2-((*R*)-2-(cyclopropylamino)-2-oxo-1-(2-phenoxyacetamido)ethyl)-5,5-dimethylthiazolidine-4-carboxylate (**2e**): yield 64%; ¹H NMR (400 MHz, CDCl₃): δ 7.55 (d, 1H, *J* = 7.7 Hz), 7.29 (m, 2H), 7.01 (m, 2H), 6.80 (m, 1H), 5.17 (d, 1H, *J* = 8.0 Hz), 4.51 (s, 1H), 4.50 (s, 2H), 3.75 (s, 3H), 3.66 (s, 1H), 2.70 (m, 1H), 1.53 (s, 3H), 1.19 (s, 3H), 0.73 (m, 2H), 0.49 (m, 2H); ¹³C NMR (100 MHz, CDCl₃): δ 170.1, 169.8, 168.9, 157.2, 129.7, 122.1, 114.8, 72.7, 67.2, 65.8, 58.3, 56.8, 52.3, 27.0, 26.6, 22.7, 6.5, 6.4; HRMS (FAB) calcd. for C₂₀H₂₈N₃O₅S [M+H]⁺: *m/z* 422.1749; found: 422.1739.

(2*R*,4*S*)-Methyl 5,5-dimethyl-2-((*R*)-2-(nonylamino)-2-oxo-1-(2-phenoxyacetamido)ethyl)thiazolidine-4-carboxylate (**2f**): yield 58%; ¹H NMR (400 MHz, CDCl₃): δ 7.58 (d, 1H, *J* = 8 Hz), 7.24 (m, 2H), 6.98 (m, 1H), 6.90 (m, 2H), 6.84 (m, 1H), 5.15 (m, 1H), 4.57 (m, 1H), 4.48 (s, 1H), 3.71 (s, 3H), 3.68 (s, 1H), 3.51 (m, 1H), 3.17 (m, 2H), 1.51 (s, 3H), 1.45 (m, 2H), 1.21 (m, 14H), 1.17 (s, 3H), 0.83 (m, 3H); ¹³C NMR (100 MHz, CDCl₃): δ 169.8, 168.8, 168.7, 157.2, 129.6, 122.0, 114.8, 72.6, 67.3, 66.0, 58.3, 57.0, 52.1, 39.7, 31.8, 29.5, 29.4, 29.3, 29.2, 27.1, 26.9, 26.7, 22.6, 14.1; HRMS (FAB) calcd. for C₂₆H₄₂N₃O₅S [M+H]⁺: *m/z* 508.2845; found: 508.2828.

2.4. Procedure for synthesis of intermediate disodium salt of 8-hydroxyphenillic acid (3)

Disodium 3,3-dimethyl-8-oxo-4-thia-1,7-diazabicyclo[3.3.0]octane-2,6-dicarboxylic acid (**3**): compound **3** was prepared in the method modified from Johnson and Hardcastle [17]. 4.5 g of 6-APA was dissolved in 100 mL of water containing 3.5 g (2.0 equiv.) of sodium bicarbonate. Carbon dioxide from dry ice was bubbled through the stirred mixture at room temperature for 24 h. The concentrated aqueous solution was then lyophilized overnight to yield 6.2 g (90%) of the product **3** as a pale yellow powder. Mp 228–230 °C (dec.). ¹H NMR (400 MHz, D₂O): δ 5.44 (d, 1H, *J* = 2.0 Hz), 4.15 (s, 1H), 4.13 (d, 1H, *J* = 2.0 Hz), 1.47 (s, 3H), 1.42 (s, 3H); ¹³C NMR (125 MHz, D₂O): δ 177.5, 175.9, 164.4, 73.6, 69.4,

59.5, 57.7, 31.5, 25.8; HRMS (FAB) calcd. for $C_9H_{11}N_2Na_2O_5S$ $[M+H]^+$: m/z 305.0184; found: 305.0174.

2.5. Procedure for alkylation of 8-hydroxypenicillic acid to synthesize compounds **4a–4d**

(3*S*,7*R*,7*aR*)-Dimethyl 2,2-dimethyl-5-oxohexahydroimidazo[5,1-*b*]thiazole-3,7-dicarboxylate (**4a**): compound **4a** was prepared in the method of Johnson and Hardcastle [17]. The synthesis of the dimethyl ester was initiated by dissolving the disodium salt **3** (2.0 g, 6.6 mmol) in DMF (50 mL) and methyl iodide (3.0 mL, 48.1 mmol) was added and stirred at room temperature for 12 h, water was added to the reaction mixture and extracted with (3 × 100 mL) diethyl ether, dried and concentrated. The crude product was purified by flash silica gel column chromatography using EtOAc/hexane (1:1) as an eluent. Pure compound **4a** (1.14 g, 60%) was isolated as a white solid. Mp: 164–166 °C. 1H NMR (400 MHz, $CDCl_3$): δ 5.89 (s, 1H), 5.78 (d, 1H, J = 1.48 Hz), 4.70 (s, 1H), 4.35 (d, 1H, J = 1.52 Hz), 3.85 (s, 3H), 3.78 (s, 3H), 1.57 (s, 3H), 1.49 (s, 3H); ^{13}C NMR (100 MHz, $CDCl_3$): δ 170.2, 169.3, 161.2, 70.8, 68.2, 58.6, 58.3, 53.2, 52.1, 33.7, 26.4. HRMS (FAB) calcd for $C_{11}H_{17}N_2O_5S$ $[M+H]^+$: m/z 289.0788; found 289.0864.

(3*S*,7*R*,7*aR*)-Dipropyl 2,2-dimethyl-5-oxohexahydroimidazo[5,1-*b*]thiazole-3,7-dicarboxylate (**4b**): yield 62%; mp 119–120 °C; 1H NMR (400 MHz, $CDCl_3$): δ 6.20 (s, 1H), 5.78 (s, 1H), 4.69 (s, 1H), 4.33 (s, 1H), 4.16 (d, 2H, J = 6.72 Hz), 4.10 (dd, 2H, J = 6.8, 13.5 Hz), 1.66 (m, 4H), 1.55 (s, 3H), 1.48 (s, 3H), 0.95 (q, 6H, J = 8.0 Hz); ^{13}C NMR (100 MHz, $CDCl_3$): δ 169.9, 168.9, 161.5, 70.8, 68.4, 67.9, 66.9, 58.6, 58.5, 34.0, 26.4, 21.8, 10.5, 10.2; HRMS (FAB) calcd. for $C_{15}H_{25}N_2O_5S$ $[M+H]^+$: m/z 345.1484; found: 345.1496.

(3*S*,7*R*,7*aR*)-Dibenzyl 2,2-dimethyl-5-oxohexahydroimidazo[5,1-*b*]thiazole-3,7-dicarboxylate (**4c**): yield 63%; mp 133–134 °C; 1H NMR (400 MHz, $CDCl_3$): δ 7.35–7.28 (m, 10H), 5.95 (s, 1H), 5.83 (d, 1H, J = 1.4 Hz), 5.22 (m, 2H), 5.17 (s, 2H), 4.74 (s, 1H), 3.37 (d, 1H, J = 1.36 Hz), 1.54 (s, 3H), 1.42 (s, 3H); ^{13}C NMR (100 MHz, $CDCl_3$): δ 169.6, 168.7, 161.3, 134.9, 134.7, 128.8, 128.7, 128.6, 128.5, 70.7, 68.3, 68.0, 67.2, 58.8, 58.4, 33.9, 26.4; HRMS(FAB) calcd. for $C_{23}H_{25}N_2O_5S$ $[M+H]^+$: m/z 441.1484; found: 441.1485.

(3*S*,7*R*,7*aR*)-Bis(2-(diethylamino)ethyl) 2,2-dimethyl-5-oxohexahydroimidazo[5,1-*b*]thiazole-3,7-dicarboxylate (**4d**): to a suspension of *N,N*-diethylaminoethyl bromide hydrobromide (1.05 g, 4.0 mmol) in 15 mL of dry DMF was added sodium bicarbonate (1.26 g, 15 mmol). The suspension was stirred at room temperature for 2 h, then disodium salt of 8-hydroxypenicillic acid **3** (500 mg, 1.6 mmol) was added. The reaction mixture was allowed to stir at room temperature overnight. Water (10 mL) was added to the reaction mixture and extracted with diethyl ether (3 × 50 mL). The organic layer was dried over Na_2SO_4 and concentrated to obtain a colorless semi-solid **4d** 189 mg (40%). IR: 3236, 3104, 2972, 2807, 1731, 1613, 1456, 1382, 1176, 1122 cm^{-1} . 1H NMR (400 MHz, $CDCl_3$): δ 6.65 (s, 1H), 5.73 (d, 1H, J = 1.58 Hz), 4.64 (s, 1H), 4.32 (d, 1H, J = 1.56 Hz), 4.24 (t, 2H, J = 5.64 Hz), 4.17 (t, 2H, J = 6.0 Hz), 2.74–2.67 (m, 4H), 2.60–2.51 (m, 8H), 1.53 (s, 3H), 1.47 (s, 3H), 1.02–0.97 (m, 12H); ^{13}C NMR (100 MHz, $CDCl_3$): δ 169.9, 168.8, 161.5, 70.8, 68.3, 64.0, 58.3, 58.5, 51.0, 50.8, 47.3, 47.2, 33.7, 26.4, 11.9, 11.6; HRMS (FAB) calcd. for $C_{21}H_{39}N_4O_5S$ $[M+H]^+$: m/z 459.2641; found: 459.2640.

2.6. Procedure for alkylation of 8-hydroxypenicillic acid methyl ester at position *N*-7 to synthesize compounds **5a** and **5b**

(3*S*,7*R*,7*aR*)-Dimethyl 6-benzyl-2,2-dimethyl-5-oxohexahydroimidazo[5,1-*b*]thiazole-3,7-dicarboxylate (**5a**): benzyl bromide (2.05 g, 1.2 mmol) and anhydrous K_2CO_3 (2.5 mg, 1.8 mmol) were

added to a vigorously stirred solution of **4a** (200 mg, 0.7 mmol) in DMF and stirring was continued for 3 h at 40–45 °C. The mixture was filtered, and the filtrate was diluted with water and extracted with diethyl ether. The extracts were dried over anhydrous Na_2SO_4 and the organic solvent was evaporated. The crude product was purified by flash column chromatography with EtOAc/hexane (1:2) as an eluent to obtain a white semi-solid **5a**. Yield 49%; IR: 2954, 1720, 1418, 1369, 1206 cm^{-1} ; 1H NMR (400 MHz, $CDCl_3$): δ 7.36–7.25 (m, 5H), 5.63 (d, 1H, J = 1.2 Hz), 5.06 (d, 1H, J = 15.2 Hz), 4.83 (s, 1H), 4.21 (d, 1H, J = 15.2 Hz), 4.08 (d, 1H, J = 1.3 Hz), 1.57 (s, 3H), 1.49 (s, 3H); ^{13}C NMR (100 MHz, $CDCl_3$): δ 169.6, 169.5, 160.1, 135.3, 128.8, 129.2, 127.9, 71.3, 67.0, 60.6, 58.3, 52.9, 52.0, 46.3, 33.9, 26.6; HRMS(FAB) calcd. for $C_{19}H_{22}N_2O_5S_2$ $[M+H]^+$: m/z 379.1327; found: 379.1334.

(3*S*,7*R*,7*aR*)-Dimethyl 6-(benzo[d]thiazol-2-ylmethyl)-2,2-dimethyl-5-oxohexahydroimidazo[5,1-*b*]thiazole-3,7-dicarboxylate (**5b**): yield 40%; 1H NMR (400 MHz, $CDCl_3$): δ 7.99 (d, 1H, J = 8.2 Hz), 7.89 (d, 1H, J = 8.0 Hz), 7.48 (t, 1H, J = 8.0 Hz), 7.43 (t, 1H, J = 8.0 Hz), 5.71 (d, 1H, J = 1.7 Hz), 5.38 (d, 1H, J = 16.6 Hz), 4.83 (s, 1H), 4.77 (d, 1H, J = 16.5 Hz), 4.51 (d, 1H, J = 1.7 Hz), 3.81 (s, 3H), 3.79 (s, 3H), 1.64 (s, 3H), 1.50 (s, 3H); ^{13}C NMR (100 MHz, $CDCl_3$): δ 169.3, 166.7, 159.7, 153.0, 135.4, 126.3, 125.4, 123.2, 121.9, 71.2, 66.9, 61.5, 58.4, 53.1, 52.1, 44.9, 34.0, 26.7; HRMS (FAB) calcd. for $C_{18}H_{22}N_3O_5S_2$ $[M+H]^+$: m/z 436.1001; found: 436.1014.

3. Results and discussion


3.1. Synthesis of thiazolidine amides through opening the β -lactam ring of penicillin V

Treatment of penicillin V with methyl iodide in DMF was carried out. Penicillin V methyl ester (**1**) as an intermediate was isolated and purified. With compound **1** available we developed an efficient procedure for generating a number of penicillin derivatives. Based on a parallel synthesis strategy, our method was to synthesize penicillin derivatives through opening the β -lactam ring of intermediate **1** with amines, which attacks the carbonyl group of β -lactam ring to form thiazolidine amides (Scheme 1). This synthetic approach was developed amenable to automation, enabling us to generate tens of compounds in a week using a Mettler Toledo MiniBlock Suite for library preparation and compound handling. In parallel, reaction of compound **1** with various aromatic, aliphatic and heterocyclic amines was carried out in six reactors, respectively. Six products (**2a–2f**) were produced simultaneously. They were purified and characterized by 1H NMR and ^{13}C NMR spectra and HRMS.


3.2. Synthesis of 8-hydroxypenicillic acid derivatives through β -lactam ring rearrangement of 6-APA

The rearrangement of the β -lactam ring started from 6-APA following our method (Scheme 2) modified from Johnson and Hardcastle [17]. Treatment of 6-APA with carbon dioxide was carried out in sodium bicarbonate aqueous solution. 6-APA was dissolved in water containing sodium bicarbonate. Carbon dioxide from a dry ice source was bubbled through the stirred mixture. The concentrated aqueous solution was then lyophilized to obtain the disodium salt of 8-hydroxypenicillic acid in high yield. The 8-hydroxypenicillic acid (isolated as the disodium salt by lyophilization) was characterized by 1H NMR and ^{13}C NMR spectroscopy and HRMS. The NMR spectra of the disodium salt of 8-hydroxypenicillic acid were well resolved and displayed no unassigned signals of significant intensity. The similar 1H NMR chemical shifts have been previously observed [18,21]. Furthermore our ^{13}C NMR chemical shifts are the same as the previous report [18,21].


Using a parallel synthetic strategy, alkylation of 8-hydroxypenicillic acid was initiated on MiniBlock by treatment of its disodium

Scheme 1. Ring opening of β -lactams of penicillin V methyl ester.

salt **3** with various aliphatic and aromatic halides as shown in Scheme 3. Disodium salt **3** was dissolved in DMF, and methyl iodide or benzyl bromide or propane iodide was added into the solution. The crude residues were purified to obtain pure products **4a–4c** as white solids in moderate yields. Since *N,N*-diethylaminoethyl bromide hydrobromide was employed for the synthesis of **4d**, excess sodium bicarbonate was added first into the solution to quench the hydrobromide acid. Compound **4d** was isolated by extracting with diethyl ether from the water solution of the reaction mixture. Products (**4a–4d**) were confirmed by ^1H and ^{13}C NMR spectra and HRMS. In the ^1H NMR spectra of compound **4b**, two 2-proton multiplet peaks of methylene groups at δ 4.17 were indicative of the formation of propyl esters at C₃ and C₆ positions. The complex patterns at δ 7.38 and 5.16 affirmed the presence of benzyl methyl esters in the compound **4c**. For product **4d**, the patterns at δ 4.25, 4.17, 2.74, 2.60, 0.97 confirmed the formation of diethylaminoethyl esters.




Scheme 2. Synthesis of disodium salt of 8-hydroxypenicillic acid from 6-APA.



Scheme 3. Synthesis of 8-hydroxypenicillic acid esters.

Furthermore, alkylation of 8-hydroxypenicillic acid methyl ester (**4a**) was carried out at its N-7 position with benzyl bromide or 2-(bromomethyl)benzo[d]thiazole using potassium carbonate as base in DMF (Scheme 4). Benzyl bromide and anhydrous potassium carbonate were added to a solution of **4a** in DMF and the mixture was stirred. The crude product was purified to obtain a pure product **5a** as a white semi-solid in modest yield. Similar procedure was proceeded for the synthesis of **5b** by using 2-(bromomethyl)benzo[d]thiazole as an alkylation reagent. Compounds **5a** and **5b** were identified by ^1H NMR and ^{13}C NMR and HRMS. In the ^1H NMR spectra of compound **5a**, the chemical shift of the methylene in the benzyl group supported the benzyl alkylation at N-7 position, and the signals from its β -lactam protons were identical in position and pattern with those in the spectrum of the starting penicillic acid methyl ester **4a**. For product **5b**, the complex patterns of benzo[d]thiazol-2-ylmethyl group confirmed the achievement of alkylation at N-7 position by 2-(bromomethyl)-benzo[d]thiazole.

In the past six decades, numerous penicillin derivatives were synthesized [1–11] through chemical modification. This led to marketing of several antibiotics [3–10]. According to our SciFinder search, six amides from β -lactam ring opening and five esters by penicillin β -lactam ring rearrangement in this work are new. The compounds were deposited into NIH Small Molecule Repository. They were screened and their biological results were deposited into PubChem [22]. The biological activity can be found by using compound identification (CID) numbers. Compound **2a** (CID 24747544) inhibits human tyrosyl-DNA phosphodiesterase 1 (TDP1) [22]; compound **2e** (CID 24747364) modulates the interaction between C-terminal C-end Rule (CendR) and neuropilin-1 (NRP-1) [22]; compound **2f** (CID 24747549) inhibits KCNQ2 potassium channels [22]; compound **4b** (CID 24747497) enhances the survival of human induced pluripotent stem cells [22];



Scheme 4. Alkylation of 8-hydroxypenicillic acid methyl ester at N-7 position.

compound **4c** (CID 24747437) can identify antagonists of the human trace amine associated receptor 1 (TAAR1) [22].

4. Conclusion

Chemical arrangements of penicillin β -lactam ring were undertaken in this work. Six thiazolidine amides were synthesized through N₄-C₇ β -lactam ring opening of penicillin V methyl ester with various aliphatic, aromatic, and heterocyclic primary amines. Five 8-hydroxypenicillic acid derivatives with side chains of methyl, propyl, benzyl, diethylaminoethyl, and 2-(bromomethyl)benzo[d]thiazole groups were yielded via β -lactam ring rearrangement from 6-aminopenicillanic acid (6-APA). Parallel synthetic methods were developed for esterification of 8-hydroxypenicillic acid and β -lactam ring opening of penicillin V methyl ester. The compounds display biological activities.

References

- [1] K.B. Hoten, E.M. Onusko, Appropriate prescribing of oral β -lactam antibiotics, *Am. Fam. Physician* 62 (2000) 611–620.
- [2] G. Lukacs, Recent Progress in the Chemical Synthesis of Antibiotics and Related Microbial Products, vol. 2, Springer, Berlin, 1993p. 621.
- [3] G. Veinberg, M. Vorona, M. Shestakova, I. Kanepe, E. Lukevics, Design of β -lactams with mechanism based nonantibacterial activities, *Curr. Med. Chem.* 10 (2003) 1741–1757.
- [4] R.R. Gupta, Topics in Heterocyclic Chemistry, Springer, Berlin/Heidelberg, 2010p. 394.
- [5] J.D. Rothstein, S. Patel, M.R. Regan, et al., β -Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression, *Nature* 433 (2005) 73–77.
- [6] P.G. Sammes, Recent chemistry of the β -lactam antibiotics, *Chem. Rev.* 76 (1976) 113–155.
- [7] A.K. Mukerjee, A.K. Singh, β -Lactams: retrospect and prospect, *Tetrahedron* 34 (1978) 1731–1767.
- [8] G.H. Hakmelahi, K.S. Shia, C. Xue, et al., Design, synthesis, and biological evaluation of a series of β -lactam-based prodrugs, *Bioorg. Med. Chem.* 10 (2002) 3489–3498.
- [9] T.L. Gilchrist, Heterocyclic Chemistry, 2nd ed., Longman Press, Harlow, 1997.
- [10] S. Wolfe, S. Ro, C.K. Kim, Z. Shi, Synthesis and decarboxylation of Δ^2 -cephem-4 4-dicarboxylic acids, *Can. J. Chem.* 79 (2001) 1238–1258.
- [11] B. Alcaide, P. Almendros, C. Aragoncillo, β -Lactams: versatile building blocks for the stereoselective synthesis of non β -lactam products, *Chem. Rev.* 107 (2007) 4437–4492.
- [12] B. Alcaide, P. Almendros, G. Cabrero, M.P. Ruiz, Stereoselective cyanation of 4-formyl and 4-imino- β -lactams: application to the synthesis of polyfunctionalized γ -lactams, *Tetrahedron* 68 (2012) 10761–10768.
- [13] B. Alcaide, P. Almendros, A. Luna, et al., Controlled rearrangement of lactam-tethered allenols with brominating reagents: a combined experimental and theoretical study on α -versus β -keto lactam formation, *Chem. Eur. J.* 17 (2011) 11559–11566.
- [14] S. Dekeukeleire, M. D'hooghe, N. De Kimpe, Diastereoselective synthesis of bicyclic gamma-lactams via ring expansion of monocyclic β -lactams, *J. Org. Chem.* 74 (2009) 1644–1649.
- [15] W. Van Brabant, N. De Kimpe, Electrophile-induced ring expansions of β -lactams toward γ -lactams, *J. Org. Chem.* 70 (2005) 8717–8722.
- [16] A.K. Mukerjee, A.K. Singh, Reactions of natural and synthetic β -lactams, *Synthesis-Stuttgart* 9 (1975) 547–589.
- [17] D.A. Johnson, G.A. Hardcastle Jr., Reaction of 6-aminopenicillanic acid with carbon dioxide, *J. Am. Chem. Soc.* 83 (1961) 3534–3535.
- [18] R.F. Pratt, M. Dryjanski, E.S. Wun, V.M. Marathias, 8-Hydroxypenicillic acid from 6-aminopenicillanic acid: a new reaction catalyzed by a class C β -lactamase, *J. Am. Chem. Soc.* 118 (1996) 8207–8212.
- [19] C.C. Ruddle, T.P. Smyth, Exploring the chemistry of penicillin as a β -lactamase-dependent prodrug, *Org. Biomol. Chem.* 5 (2007) 160–168.
- [20] L. Heinisch, S. Wittmann, T. Stoiber, et al., Highly antibacterial active aminoacyl penicillin conjugates with acylated bis-catecholate siderophores based on secondary diamino acids and related compounds, *J. Med. Chem.* 45 (2002) 3032–3040.
- [21] A.F. Casy, A. Lipczynski, 8-Hydroxypenicillic acid: NMR characteristics and facile formation from 6-aminopenicillanic acid, *J. Pharm. Pharmacol.* 46 (1994) 533–534.
- [22] PubChem: <https://pubchem.ncbi.nlm.nih.gov>. The compound identification (CID) numbers are 24747544 (2a), 24747436 (2b), 24747499 (2c), 24747495 (2d), 24747364 (2e), 24747549 (2f), 25011528 (3), 25011526 (4a), 24747497 (4b), 24747437 (4c), 25011527 (5a), 24789294 (5b).